At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02637 HAIXI PHARMA
Market Closed 10-30 16:08:06
139.300
-1.700
-1.21%
High142.000
Low138.500
Vol26.95K
Open140.000
D1 Closing141.000
Amplitude2.48%
Mkt Cap10.96B
Tradable Cap10.96B
Total Shares78.71M
T/O3.79M
T/O Rate0.03%
Tradable Shares78.71M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Institutional Research Coverage Signals Market Direction, Can Accelerated Innovation Transformation Drive HAIXI PHARMA (02637) Valuation Recovery?
Hong Kong Stock Movement: HAIXI PHARMA (02637) Rises Over 5% Intraday; HX9428 Expected to Enter BD Negotiations as Optimal Window Opens to Accelerate Global Phase 3 Development Through Partnerships
Fujian Haixi Innovative Drug Development Co., Ltd. was established on March 27, 2012. The company is a commercial-stage pharmaceutical firm that integrates R&D, manufacturing and sales capabilities, and maintains a pipeline of innovative drug candidates. It owns a diversified product portfolio and pipeline across China’s largest and fastest-growing therapeutic areas. As of the latest practicable date, its commercialized portfolio consists mainly of generics for digestive, cardiovascular, endocrine, neurological and inflammatory diseases. According to CIC, these therapeutic areas accounted for over 25 % of China’s total pharmaceutical sales in 2023. The company’s innovative pipeline focuses on drug candidates for multiple indications, including a potential first-in-class oncology asset, a potential first-in-class oral therapy for wet age-related macular degeneration (wAMD) / diabetic macular edema (DME) / retinal vein occlusion (RVO), and two additional pre-clinical-stage innovative programs for oncology and respiratory diseases. All innovative drug candidates are developed and advanced internally through proprietary technologies.